Neurocrine Bio. (NBIX) PT Raised to $32 at Jefferies

Jefferies analyst Thomas Wei reiterated a Buy rating and boosted his price target on Neurocrine Bio. (NASDAQ: NBIX) to $32.00 (from $24.00)

Wei commented, "Both doses of Elagolix hit both co-primary pain endpoints in the first of its two ongoing Phase 3 trials in premenopausal women with endometriosis. While we had expected positive results from this trial, the consistent efficacy and safety profile solidify our confidence in NBIX’s lead product candidate."

For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.

Shares of Neurocrine Bio. closed at $27.48 yesterday.

You May Also Be Interested In

• Cummins (CMI) PT Lowered to $675 at Jefferies
• UBS Downgrades Klarna (KLAR) to Neutral
• Stella International Holdings (1836:HK) (SLNLF) PT Lowered to HK$10 at Macquarie